SCHEMBL6795756

SCHEMBL6795756

Cc1cccc(-c2ccccc2C(=O)Nc2ccc(NCCc3ccccn3)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.53
SMO Q99835 2/20 0.48
LMNA P02545 2/20 0.47
HTT P42858 1/20 0.47
ALDH1A1 P00352 2/20 0.46
CTNNB1 P35222 2/20 0.46
TCF7L2 Q9NQB0 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
CDK4 P11802 1/20 0.44
CCND1 P24385 1/20 0.44
CHRNB2 P17787 2/20 0.44
CHRNB4 P30926 2/20 0.44
CHRNA3 P32297 2/20 0.44
CHRNA4 P43681 2/20 0.44
SYK P43405 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6787263 0.89 HTT (0.49) L3MBTL1SMOLMNAHTTALDH1A1
SCHEMBL6796673 0.88 HTT (0.59) L3MBTL1SMOLMNAHTTALDH1A1
SCHEMBL7080737 0.88 SMN1; SMN2 (0.50) L3MBTL1SMOLMNAHTTALDH1A1
SCHEMBL6795360 0.88 CNR1 (0.50) SMOLMNAHTTALDH1A1KDM4E
Hydrochloric Acid SCHEMBL6791064 0.88 NPC1 (0.49) L3MBTL1SMOLMNAHTTALDH1A1
SCHEMBL6799491 0.87 TAS1R3 (0.53) L3MBTL1SMOLMNAHTTALDH1A1
SCHEMBL6794256 0.87 NPC1 (0.55) SMOLMNAHTTALDH1A1KDM4E
SCHEMBL6498069 0.87 HDAC7 (0.49) L3MBTL1SMOLMNAHTTCTNNB1
SCHEMBL6492508 0.87 SMN1; SMN2 (0.52) L3MBTL1SMOLMNAHTTCTNNB1
SCHEMBL6795302 0.87 TAS1R3 (0.47) L3MBTL1SMOLMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 L3MBTL1 1793/4885SMO 2094/4885LMNA 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.